<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30038001</article-id>
<article-id pub-id-type="pmc">6094149</article-id>
<article-id pub-id-type="publisher-id">201800931</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1800931115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Medical Sciences</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Tsix–Mecp2 female mouse model for Rett syndrome reveals that low-level MECP2 expression extends life and improves neuromotor function</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Carrette</surname>
<given-names>Lieselot L. G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blum</surname>
<given-names>Roy</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Weiyuan</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelleher</surname>
<given-names>Raymond J.</given-names>
<suffix>III</suffix>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jeannie T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup><institution>Howard Hughes Medical Institute</institution>, Massachusetts General Hospital, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff2"><sup>b</sup>Department of Molecular Biology, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff3"><sup>c</sup>Department of Genetics, <institution>Harvard Medical School</institution>, Boston, <addr-line>MA</addr-line> 02115;</aff>
<aff id="aff4"><sup>d</sup>Center for Medical Genetics, <institution>Ghent University</institution>, 9000 Ghent, <country>Belgium</country>;</aff>
<aff id="aff5"><sup>e</sup>Center for Genomic Medicine, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff6"><sup>f</sup>Department of Neurology, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>lee@molbio.mgh.harvard.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Jeannie T. Lee, June 20, 2018 (sent for review January 17, 2018; reviewed by Michela Fagiolini and Monica J. Justice)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: L.L.G.C. and J.T.L. designed research; L.L.G.C. performed research; R.B., W.M., and R.J.K. contributed analytic tools; L.L.G.C. and J.T.L. analyzed data; and L.L.G.C. and J.T.L. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: M.F., Boston Children’s Hospital and Harvard Medical School; and M.J.J., The Hospital for Sick Children.</p>
</fn>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>7</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>115</volume>
<issue>32</issue>
<fpage>8185</fpage>
<lpage>8190</lpage>
<permissions>
<copyright-year>2018</copyright-year>
<license>
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/"></ali:license_ref>
<license-p>Published under the <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/site/aboutpnas/licenses.xhtml">PNAS license</ext-link>.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201800931.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused by mutations in <italic>MECP2</italic>. To treat RTT, reactivating the dormant copy of <italic>MECP2</italic> on the inactive X has been of considerable interest. Although potential therapeutics have been identified, their development has been hampered by the lack of a suitable female mouse model and uncertainty regarding how much MECP2 needs to be restored. Here, we create a female model with a more severe phenotype, including a short lifespan, neuromotor impairment, and repetitive behaviors often seen in human RTT. Significantly, 5–10% MECP2 restoration in brain extends lifespan by eightfold and improves RTT phenotypes. Our study thus provides a much-needed female model and implies potential therapeutic benefit with low-level MECP2 expression.</p>
</abstract>
<abstract>
<p>Rett syndrome (RTT) is a severe neurodevelopmental disorder caused by a mutation in the X-linked methyl-CpG-binding protein 2 (MECP2). There is currently no disease-specific treatment, but MECP2 restoration through reactivation of the inactive X (Xi) has been of considerable interest. Progress toward an Xi-reactivation therapy has been hampered by a lack of suitable female mouse models. Because of cellular mosaicism due to random X-chromosome inactivation (XCI), <italic>Mecp2</italic><sup>+/−</sup> heterozygous females develop only mild RTT. Here, we create an improved female mouse model by introducing a mutation in <italic>Tsix</italic>, the antisense regulator of XCI allelic choice. <italic>Tsix–Mecp2</italic> mice show reduced MECP2 mosaicism and closely phenocopy the severely affected <italic>Mecp2</italic>-null males. <italic>Tsix–Mecp2</italic> females demonstrate shortened lifespan, motor weakness, tremors, and gait disturbance. Intriguingly, they also exhibit repetitive behaviors, as is often seen in human RTT, including excessive grooming and biting that result in self-injury. With a <italic>Tsix</italic> allelic series, we vary MECP2 levels in brain and demonstrate a direct, but nonlinear correlation between MECP2 levels and phenotypic improvement. As little as 5–10% MECP2 restoration improves neuromotor function and extends lifespan five- to eightfold. Our study thus guides future pharmacological strategies and suggests that partial MECP2 restoration could have disproportionate therapeutic benefit.</p>
</abstract>
<kwd-group>
<kwd>Rett syndrome</kwd>
<kwd>MECP2</kwd>
<kwd>X reactivation</kwd>
<kwd>Tsix</kwd>
<kwd>Xist</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Rett Syndrome research trust</funding-source>
<award-id rid="sp1">NA</award-id>
<principal-award-recipient>Jeannie T. Lee</principal-award-recipient>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">International Rett Syndrome Foundation (IRSF)<named-content content-type="funder-id">100001819</named-content></funding-source>
<award-id rid="sp2">NA</award-id>
<principal-award-recipient>Jeannie T. Lee</principal-award-recipient>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Howard Hughes Medical Institute (HHMI)<named-content content-type="funder-id">100000011</named-content></funding-source>
<award-id rid="sp3">NA</award-id>
<principal-award-recipient>Jeannie T. Lee</principal-award-recipient>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">Simons Foundation<named-content content-type="funder-id">100000893</named-content></funding-source>
<award-id rid="sp4">NA</award-id>
<principal-award-recipient>Raymond J Kelleher III</principal-award-recipient>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">Belgian American Educational Foundation (B.A.E.F.)<named-content content-type="funder-id">100001491</named-content></funding-source>
<award-id rid="sp5">NA</award-id>
<principal-award-recipient>Lieselot L. G. Carrette</principal-award-recipient>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>